Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority
Executive Summary
Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York
You may also be interested in...
Schering Licensing Decisions To Focus On Boosting Sales Efficiency – Hassan
Schering-Plough's licensing efforts will focus on bringing in compounds that will increase the efficiency of the firm's marketing efforts, CEO Fred Hassan suggested during an interview with "The Pink Sheet."
Schering Licensing Decisions To Focus On Boosting Sales Efficiency – Hassan
Schering-Plough's licensing efforts will focus on bringing in compounds that will increase the efficiency of the firm's marketing efforts, CEO Fred Hassan suggested during an interview with "The Pink Sheet."
Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol
Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4